Bright minds biosciences and firefly neuroscience to collaborate after the breakthrough study: a phase 2 trial of bmb-101 in absence epilepsy and developmental epileptic encephalopathy for full analysis of eeg data

New york and vancouver, british columbia, oct. 21, 2024 (globe newswire) -- bright minds biosciences inc. (bright minds or the company) (nasdaq: drug), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with firefly neuroscience, inc. (firefly) (nasdaq: aiff), an artificial intelligence (ai) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (eeg) data in the company's breakthrough study, an open-label phase 2 clinical trial evaluating the safety, tolerability, and efficacy of bmb-101, a highly selective 5-ht2c receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy (dee).
DRUG Ratings Summary
DRUG Quant Ranking